IC
STOK icon

Ikarian Capital’s Stoke Therapeutics STOK Stock Holding History

Ikarian Capital’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500
Closed -$197K – 178
2023
Q3 		$197K Sell
500
-214,700
-100% -$1.41M 0.02% 121
2023
Q2 		$2.29M Buy
+215,200
New +$2.29M 0.36% 60

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ikarian Capital's STOK Position: Q1 2025 in Review

Ikarian Capital sold out of Stoke Therapeutics (STOK) in Q1 2025, closing a stake of 6,798 shares — an estimated $75K sold.

Ikarian Capital first reported a position in STOK in Q2 2023 and held it in 7 quarters. The position peaked at $748K in Q2 2023. 126 funds tracked by Wall St. Rank hold STOK as of Q1 2025.

  • Ikarian Capital reported no remaining Stoke Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 6,798 Stoke Therapeutics shares in Q1 2025, an estimated $75K.
  • Ikarian Capital first reported a position in Stoke Therapeutics in Q2 2023 and held it in 7 quarters.
  • Ikarian Capital's Stoke Therapeutics position peaked at $748K in Q2 2023.
  • 126 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.